Characterisation of Intraocular Lens Injectors.

Autor:	Friedrich M; David J. Apple International Laboratory for Ocular Pathology, Department of Ophthalmology, University Hospital Heidelberg, Germany., Munro DJ; David J. Apple International Laboratory for Ocular Pathology, Department of Ophthalmology, University Hospital Heidelberg, Germany., Auffarth GU; David J. Apple International Laboratory for Ocular Pathology, Department of Ophthalmology, University Hospital Heidelberg, Germany., Khoramnia R; David J. Apple International Laboratory for Ocular Pathology, Department of Ophthalmology, University Hospital Heidelberg, Germany.
Jazyk:	angličtina
Zdroj:	Klinische Monatsblatter fur Augenheilkunde [Klin Monbl Augenheilkd] 2024 Aug; Vol. 241 (8), pp. 905-916. Date of Electronic Publication: 2024 Aug 15.
DOI:	10.1055/a-2349-2158
Abstrakt:	In modern ophthalmic surgery, an intraocular lens (IOL) is commonly implanted into the patient's eye with an IOL injector. Many injectors are available, showing various technological differences, from the early manually loaded injector systems to the modern preloaded injectors. This review aims to give a concise overview of the defining characteristics of injector models and draws attention to complications that may occur during IOL implantation. One can differentiate injectors according to their preoperative preparation (manually loaded or preloaded), their implantation mechanism (push-type or screw-type or combined or automated), the size of the nozzle tip, the presence of an insertion depth control feature, and the injector's reusability. Potential complications are IOL misconfigurations such as a haptic-optic adhesion, adherence of the IOL to the injector plunger, an overriding plunger, uncontrolled IOL rotation, a trapped trailing haptic, or damage to the IOL. Additionally, during IOL implantation, the nozzle can become damaged with scratches, extensions, cracks, or bursts to the tip. While these complications rarely produce long-term consequences, manufacturers should try to prevent them by further improving their devices. Similarly, surgeons should evaluate new injectors carefully to ensure the highest possible surgical safety. Competing Interests: R. K. reports grants, personal fees, and nonfinancial support from Alcon Laboratories, Inc.; personal fees and nonfinancial support from Kowa Company, Ltd.; grants, personal fees, and nonfinancial support from Hoya Surgical Optics GmbH; personal fees from Ophtec B. V.; grants and personal fees from Physiol s. a.; grants, personal fees, and nonfinancial support from Rayner; grants, personal fees, and nonfinancial support from Johnson & Johnson; nonfinancial support from Acufocus, Inc.; personal fees and nonfinancial support from Teleon; personal fees and nonfinancial support from Santen Pharmaceutical Co, Ltd.; personal fees from Oculus; all outside the submitted work. G. U. A. reports grants, personal fees, and nonfinancial support from Teleon Surgical B. V.; grants and nonfinancial support from Klaus Tschira Foundation; grants, personal fees, and nonfinancial support from Alcon Laboratories, Inc.; grants, personal fees, and nonfinancial support from J&J Vision; grants, personal fees, and nonfinancial support from Hoya Surgical Optics GmbH; grants and nonfinancial support from Kowa Company, Ltd.; personal fees from Ophtec B. V.; grants and nonfinancial support from Physiol s. a.; grants and nonfinancial support from Acufocus, Inc.; grants, personal fees, and nonfinancial support from Rayner Intraocular Lenses Ltd.; grants from Sifi S. p.A; grants, personal fees, and nonfinancial support from Santen Pharmaceutical Co, Ltd.; grants, personal fees, and nonfinancial support from Oculus; all outside the submitted work. D. J. M. and M. F. report no conflicts of interest. (Thieme. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu